NCT07784387Recruiting
A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal
High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) Retrospective Cohort Study
Source: ClinicalTrials.gov · Last updated 28 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to understand how the participants with high-risk non-muscle invasive bladder cancer are diagnosed, treated, and cared for in regular clinical practice in Portugal. HR-NMIBC is an early-stage bladder cancer that is limited to the inner lining of bladder but has a considerable high chance of cancer coming back or worsening.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 250 (estimated)
- First submitted
- 5 Aug 2026
- Start date
- 25 Aug 2026
- Primary completion date
- 15 Feb 2028
- Lead sponsor
- Janssen-Cilag Farmaceutica Ltda.
- Diseases
- Bladder cancer
- NCT number
- NCT07784387
What you commit to
- Study type: Observational
- Planned participants: 250
- From 25 Aug 2026 to the primary completion date, 15 Feb 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of radical cystectomy performed either prior to the HR-NMIBC index diagnosis or for an indication unrelated to the index HR-NMIBC
Other
- Tumor stage at diagnosis classified as TaG1-2, T2-T4, N1-3, or M1
- Participation in any interventional clinical trial during the observation period
Who the study is looking for
- Bladder cancer diagnosis between January 1, 2016 and December 31, 2020
- Tumor stage N0/x and M0/x plus any of the following: Tis (primary CIS); TaG3/HG (high-grade non-invasive papillary carcinoma); or T1 (tumor invading subepithelial connective tissue)
- Minimal follow-up time of 5 years unless there is premature death event
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IPO Lisboa Coordinator of this site? Confirm its status | Lisbon | Portugal | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.